Skip to main content
. 2002 Dec 15;8(6):1019–1022. doi: 10.3748/wjg.v8.i6.1019

Table 3.

The therapeutic efficiency of intraperitoneal thermochemotherapy combined with IL-2 immunotherapy

Groups n Intraperitoneal recurrent rate (%) Hepatic metastasis rate(%) 3-year survival rate(%)
Group I 65 29.2(19/65) 16.9(11/65) 47.7(31/65)
Group II 73 12.3(9/73)b 10.9(8/73)a 65.8(48/73)a
a

P < 0.05 vs control group,

b

P < 0.01 vs control group